Metraipolis › archive › dc_0614a4ede720

Combined omalizumab and desensitization to control IgE-mediated hypersensitivity in enzyme replacement therapy for late-onset Pompe disease — Europe PMC PMID:42135804

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42135804
DOI
10.1186/s13023-[numero omesso]-4
License (as archived)
solo-consultazione
Archived
2026-10-08T00:44:50.439Z
SHA-256 of the archived text
329f857ad56a251e757e58b2a5076a8ba171af4bcae04721be487ca180ece06a
Stable URL of this page
https://metraipolis.com/documento/dc_0614a4ede720

How to cite

Combined omalizumab and desensitization to control IgE-mediated hypersensitivity in enzyme replacement therapy for late-onset Pompe disease — Europe PMC PMID:42135804 — Europe PMC (en), https://europepmc.org/article/MED/42135804 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_0614a4ede720 (Metraipolis archive dc_0614a4ede720, sha256 329f857ad56a251e757e58b2a5076a8ba171af4bcae04721be487ca180ece06a)
BibTeX
@misc{dc0614a4ede720,
  title = {Combined omalizumab and desensitization to control IgE-mediated hypersensitivity in enzyme replacement therapy for late-onset Pompe disease — Europe PMC PMID:42135804},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42135804},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_0614a4ede720; sha256 329f857ad56a251e757e58b2a5076a8ba171af4bcae04721be487ca180ece06a},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42135804. Agents can read the archived copy with the MCP tool read_document.